Lipopolysaccharide (LPS) is recognized as an inducer of the inflammatory response associated with gram-negative sepsis and systemic inflammatory response syndrome. LPS induction proceeds through Toll-like Receptor (TLR) in immune cells and intestinal epithelial cells (IEC). This report presents the first identification of Bcl10 (B-cell CLL/lymphoma 10) as a mediator of the LPS-induced activation of IL-8 in human IEC. Bcl10 is a caspase-recruitment domain (CARD)-containing protein, associated with constitutive activation of NFB in MALT (mucosa-associated lymphoid tissue) lymphomas. The normal human intestinal epithelial cell line NCM460, normal primary human colonocytes, and ex vivo human colonic tissue were exposed to 10 ng/ml of LPS for 2-6 hours. Effects on Bcl10, phospho-IB, NFB, and IL-8 were determined by Western blot, ELISA, immunohistochemistry, and confocal microscopy. Effects of Bcl10 silencing by siRNA, TLR4 blocking antibody, TLR4 silencing by siRNA, and an IRAK 1/4 inhibitor on LPS-induced activation were examined. Following Bcl10 silencing, LPS-induced increases in NFB, IB, and IL-8 were significantly reduced (p<0.001). Increasing concentrations of LPS were associated with higher concentrations of Bcl10 protein when quantified by ELISA, and the association between LPS exposure and increased Bcl10 was also demonstrated by Western blot, immunohistochemistry, and confocal microscopy. Exposure to TLR4 antibody, TLR4 siRNA, or an IRAK1/4 inhibitor eliminated the LPS-induced increases in Bcl10, NFB, and IL-8. Identification of Bcl10 as a mediator of LPS-induced activation of NFB and IL-8 in normal human IEC provides new insight into mechanisms of epithelial inflammation and new opportunities for therapeutic intervention.